TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today updates on its research and development activities and its potential investment strategies. NOX-E36 developmentsTME Pharma announces the initiation of a subsequent study for NOX-E36 and the simultaneous termination of its collaboration wi ...